First National Advisers LLC Has $3.09 Million Holdings in Edwards Lifesciences Co. (NYSE:EW)

First National Advisers LLC raised its position in Edwards Lifesciences Co. (NYSE:EW) by 0.5% in the 4th quarter, HoldingsChannel reports. The institutional investor owned 41,790 shares of the medical research company’s stock after purchasing an additional 215 shares during the period. First National Advisers LLC’s holdings in Edwards Lifesciences were worth $3,094,000 as of its most recent SEC filing.

Other institutional investors and hedge funds have also recently added to or reduced their stakes in the company. Wellington Management Group LLP raised its holdings in shares of Edwards Lifesciences by 86.3% in the 3rd quarter. Wellington Management Group LLP now owns 31,532,725 shares of the medical research company’s stock worth $2,080,845,000 after purchasing an additional 14,610,123 shares during the period. Jennison Associates LLC bought a new stake in shares of Edwards Lifesciences in the 4th quarter worth approximately $555,939,000. Assenagon Asset Management S.A. raised its holdings in shares of Edwards Lifesciences by 475.8% in the 4th quarter. Assenagon Asset Management S.A. now owns 4,243,976 shares of the medical research company’s stock worth $314,182,000 after purchasing an additional 3,506,886 shares during the period. Raymond James Financial Inc. bought a new stake in shares of Edwards Lifesciences in the 4th quarter worth approximately $213,844,000. Finally, Jacobs Levy Equity Management Inc. raised its holdings in shares of Edwards Lifesciences by 239.9% in the 3rd quarter. Jacobs Levy Equity Management Inc. now owns 3,693,663 shares of the medical research company’s stock worth $243,745,000 after purchasing an additional 2,606,950 shares during the period. Hedge funds and other institutional investors own 79.46% of the company’s stock.

Wall Street Analyst Weigh In

A number of research analysts recently weighed in on the stock. Bank of America upgraded shares of Edwards Lifesciences from a “neutral” rating to a “buy” rating and lifted their price objective for the company from $82.00 to $90.00 in a research note on Monday, December 16th. Wolfe Research lowered shares of Edwards Lifesciences from a “hold” rating to a “strong sell” rating in a research report on Wednesday, February 12th. Truist Financial restated a “hold” rating and set a $78.00 price target (up from $70.00) on shares of Edwards Lifesciences in a research report on Thursday, December 5th. Royal Bank of Canada restated an “outperform” rating and set a $85.00 price target on shares of Edwards Lifesciences in a research report on Wednesday, February 12th. Finally, Morgan Stanley boosted their price target on shares of Edwards Lifesciences from $70.00 to $75.00 and gave the company an “equal weight” rating in a research report on Wednesday, February 12th. One research analyst has rated the stock with a sell rating, fourteen have given a hold rating and twelve have assigned a buy rating to the company’s stock. According to data from MarketBeat, the stock presently has a consensus rating of “Hold” and an average target price of $79.95.

Insider Activity at Edwards Lifesciences

In related news, CEO Bernard J. Zovighian sold 6,164 shares of the stock in a transaction that occurred on Monday, March 10th. The shares were sold at an average price of $69.51, for a total transaction of $428,459.64. Following the transaction, the chief executive officer now owns 59,083 shares in the company, valued at $4,106,859.33. This represents a 9.45 % decrease in their ownership of the stock. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is available at the SEC website. Also, VP Daniel J. Lippis sold 2,500 shares of the stock in a transaction that occurred on Monday, December 16th. The shares were sold at an average price of $74.08, for a total transaction of $185,200.00. Following the transaction, the vice president now owns 23,189 shares in the company, valued at approximately $1,717,841.12. This trade represents a 9.73 % decrease in their position. The disclosure for this sale can be found here. Insiders have sold 53,803 shares of company stock worth $3,900,976 over the last 90 days. 1.29% of the stock is owned by company insiders.

Edwards Lifesciences Stock Performance

Shares of NYSE:EW opened at $69.37 on Friday. The company has a market cap of $40.78 billion, a price-to-earnings ratio of 9.95, a price-to-earnings-growth ratio of 4.82 and a beta of 1.12. The company has a 50-day moving average price of $71.74 and a 200-day moving average price of $70.33. The company has a current ratio of 3.46, a quick ratio of 2.89 and a debt-to-equity ratio of 0.06. Edwards Lifesciences Co. has a 12 month low of $58.93 and a 12 month high of $96.12.

Edwards Lifesciences (NYSE:EW) last issued its quarterly earnings data on Tuesday, February 11th. The medical research company reported $0.59 EPS for the quarter, beating the consensus estimate of $0.55 by $0.04. Edwards Lifesciences had a net margin of 72.93% and a return on equity of 19.40%. As a group, equities analysts anticipate that Edwards Lifesciences Co. will post 2.45 EPS for the current year.

Edwards Lifesciences Profile

Edwards Lifesciences Corporation provides products and technologies for structural heart disease and critical care monitoring in the United States, Europe, Japan, and internationally. It offers transcatheter heart valve replacement products for the minimally invasive replacement of aortic heart valves under the Edwards SAPIEN family of valves system; and transcatheter heart valve repair and replacement products to treat mitral and tricuspid valve diseases under the PASCAL PRECISION and Cardioband names.